United States Biotechnology & Medical Research

Roivant Sciences Ltd (ROIV)

Track

Track

Roivant Sciences experienced significant insider trading activity recently, with 46 transactions totaling over $340 million in sales. Key executives, including Mayukh Sukhatme and Eric Venker, offloaded substantial equity stakes following the latest earnings report. These divestments occurred while the stock price maintained strong momentum, trading near its 52-week high with a 19.3% quarterly gain.
Ticker: ROIV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Roivant Sciences Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Planned sale
Price
410.52
Quantity 49,947 -32.4%
Value US$4,658,559
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Planned sale
Price
217.58
Quantity 7,099 +14.4%
Value US$1,749,228
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
489.11
Quantity 76,581
Value US$1,251,323
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
36.48
Quantity 1,000 -0.8%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
36.48
Quantity 1,000
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
37.30
Quantity 1,000 -0.1%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
37.30
Quantity 1,000
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
37.17
Quantity 1,000 -0.9%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
37.17
Quantity 1,000
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
37.18
Quantity 1,000 -0.2%
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
36.59
Quantity 1,000 -0.6%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
36.73
Quantity 1,000
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
36.25
Quantity 1,000 -1.5%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
36.25
Quantity 1,000
Value US$100,000
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
36.23
Quantity 1,000 -1.3%
Value US$100,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
36.23
Quantity 243,177
Value US$8,809,768
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
34.95
Quantity 200,000 -11.0%
Value US$6,990,000
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
34.95
Quantity 200,000
Value US$6,989,924
3.5
Fitzgerald Meghan Non-Executive Director
Transaction date
Sale
Price
34.90
Quantity 10,000 -18.9%
Value US$349,000
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
35.45
Quantity 200,000 -10.3%
Value US$7,090,000
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
35.28
Quantity 12,380 -0.1%
Value US$436,766
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
35.28
Quantity 12,380 -0.1%
Value US$436,766
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
35.28
Quantity 12,380 -0.1%
Value US$436,766
3.5
MEGHAN FITZGERALD Director Non-Executive Director
Transaction date
Proposed sale
Price
34.73
Quantity 10,000
Value US$347,300
3.5
MEGHAN FITZGERALD Director Non-Executive Director
Transaction date
Proposed sale
Price
34.73
Quantity 10,000
Value US$347,300
2.0
KEITH S MANCHESTER Director Non-Executive Director
Transaction date
Proposed sale
Price
35.45
Quantity 200,000
Value US$7,090,280
1.2
Epperly Melissa B, Non-Executive Director
Transaction date
Sale
Price
34.71
Quantity 2,748 -14.3%
Value US$95,383
1.2
Epperly Melissa B, Non-Executive Director
Transaction date
Sale
Price
34.32
Quantity 15,002 -43.8%
Value US$514,869
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
34.59
Quantity 600,000 -4.2%
Value US$20,754,000
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
34.44
Quantity 200,000 -1.4%
Value US$6,888,000
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
34.59
Quantity 600,000 -4.2%
Value US$20,754,000
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
34.44
Quantity 200,000 -1.4%
Value US$6,888,000
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
34.59
Quantity 600,000 -4.2%
Value US$20,754,000
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
34.44
Quantity 200,000 -1.4%
Value US$6,888,000
1.2
MELISSA EPPERLY Director Non-Executive Director
Transaction date
Proposed sale
Price
34.07
Quantity 17,750
Value US$604,742
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
34.07
Quantity 325,000 -2.2%
Value US$11,072,750
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
33.92
Quantity 300,783 -2.0%
Value US$10,202,559
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
34.07
Quantity 325,000 -2.2%
Value US$11,072,750
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
33.92
Quantity 300,783 -2.0%
Value US$10,202,559
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
34.07
Quantity 325,000 -2.2%
Value US$11,072,750
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
33.92
Quantity 300,783 -2.0%
Value US$10,202,559
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
34.08
Quantity 500,000 -2.6%
Value US$17,040,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
34.08
Quantity 500,000
Value US$17,039,650
2.3
Sukhatme Mayukh President & CIO Executive Director
Transaction date
Sale
Price
34.13
Quantity 500,000 -2.6%
Value US$17,065,000
2.3
MAYUKH SUKHATME Officer; Director Executive Director
Transaction date
Proposed sale
Price
34.13
Quantity 500,000
Value US$17,066,500
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
33.51
Quantity 46,234 -2.8%
Value US$1,549,301
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
33.05
Quantity 153,766 -8.5%
Value US$5,081,966
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
33.16
Quantity 200,000
Value US$6,631,659
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
30.27
Quantity 200,000 -11.0%
Value US$6,054,000
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
30.27
Quantity 200,000
Value US$6,054,731
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
29.59
Quantity 200,000 -10.8%
Value US$5,918,000
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
29.59
Quantity 200,000
Value US$5,917,135
2.4
Gline Matthew CEO Executive Director
Transaction date
Sale
Price
29.16
Quantity 289,774 -1.7%
Value US$8,449,810
2.4
Gline Matthew Officer Officer
Transaction date
Proposed sale
Price
29.16
Quantity 289,774
Value US$8,449,876
2.4
Gline Matthew Officer Officer
Transaction date
Proposed sale
Price
29.16
Quantity 289,774
Value US$8,449,876
0.8
Humes Jennifer Chief Accounting Officer Officer
Transaction date
Sale
Price
28.37
Quantity 13,538 -13.9%
Value US$384,073
0.8
JENNIFER HUMES Officer Officer
Transaction date
Proposed sale
Price
28.37
Quantity 13,538
Value US$384,035
3.5
Fitzgerald Meghan Non-Executive Director
Transaction date
Sale
Price
27.45
Quantity 70,000 -62.0%
Value US$1,921,500
3.5
MEGHAN FITZGERALD Director Non-Executive Director
Transaction date
Proposed sale
Price
27.45
Quantity 70,000
Value US$1,921,458
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
28.24
Quantity 200,000 -10.8%
Value US$5,648,000
2.2
Venker Eric Officer Officer
Transaction date
Proposed sale
Price
28.24
Quantity 200,000
Value US$5,648,836
1.2
Epperly Melissa B, Non-Executive Director
Transaction date
Sale
Price
28.68
Quantity 41,861 -72.6%
Value US$1,200,573
1.2
MELISSA B EPPERLY Director Non-Executive Director
Transaction date
Proposed sale
Price
28.68
Quantity 41,861
Value US$1,200,498
1.8
Torti Frank President and Vant Chair Officer
Transaction date
Sale
Price
27.51
Quantity 587,390 -4.1%
Value US$16,159,099
1.8
Torti Frank President and Vant Chair Officer
Transaction date
Sale
Price
27.15
Quantity 1,012,610 -6.9%
Value US$27,492,362
1.8
FRANK TORTI Officer Officer
Transaction date
Proposed sale
Price
27.52
Quantity 1,600,000
Value US$44,032,000
1.8
Torti Frank President and Vant Chair Officer
Transaction date
Sale
Price
27.42
Quantity 1,400,000 -9.2%
Value US$38,388,000
1.8
FRANK TORTI Officer Officer
Transaction date
Proposed sale
Price
27.48
Quantity 1,400,000
Value US$38,472,000
2.2
Venker Eric President & Immunovant CEO Officer
Transaction date
Sale
Price
26.49
Quantity 200,000 -10.8%
Value US$5,298,000
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
26.50
Quantity 225,000 -1.5%
Value US$5,962,500
3.3
Gold Daniel Allen Non-Executive Director
Transaction date
Sale
Price
26.49
Quantity 150,784 -1.0%
Value US$3,994,268
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
26.50
Quantity 225,000 -1.5%
Value US$5,962,500
2.0
MANCHESTER KEITH S Non-Executive Director
Transaction date
Sale
Price
26.49
Quantity 150,784 -1.0%
Value US$3,994,268
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
26.50
Quantity 225,000 -1.5%
Value US$5,962,500
3.4
QVT Financial LP Director by Deputization
Transaction date
Sale
Price
26.49
Quantity 150,784 -1.0%
Value US$3,994,268
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-01 2026-08-28 PlS Planned sale
2.2
Venker Eric

President & Immunovant CEO

Officer
49,947 -32.4%
410.52
US$4,658,559 		49,947 -32.4% 410.52 US$4,658,559
2026-09-01 2026-08-28 PlS Planned sale
2.2
Venker Eric

President & Immunovant CEO

Officer
7,099 +14.4%
217.58
US$1,749,228 		7,099 +14.4% 217.58 US$1,749,228
2026-08-28 2026-08-28 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
76,581
489.11
US$1,251,323 		76,581 489.11 US$1,251,323
2026-08-21 2026-08-21 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -0.8%
36.48
US$100,000 		1,000 -0.8% 36.48 US$100,000
2026-08-21 2026-08-21 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
1,000
36.48
US$100,000 		1,000 36.48 US$100,000
2026-08-21 2026-08-20 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -0.1%
37.30
US$100,000 		1,000 -0.1% 37.30 US$100,000
2026-08-20 2026-08-20 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
1,000
37.30
US$100,000 		1,000 37.30 US$100,000
2026-08-21 2026-08-19 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -0.9%
37.17
US$100,000 		1,000 -0.9% 37.17 US$100,000
2026-08-19 2026-08-19 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
1,000
37.17
US$100,000 		1,000 37.17 US$100,000
2026-08-18 2026-08-18 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -0.2%
37.18
US$100,000 		1,000 -0.2% 37.18 US$100,000
2026-08-18 2026-08-18 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -0.6%
36.59
US$100,000 		1,000 -0.6% 36.59 US$100,000
2026-08-18 2026-08-18 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
1,000
36.73
US$100,000 		1,000 36.73 US$100,000
2026-08-18 2026-08-17 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -1.5%
36.25
US$100,000 		1,000 -1.5% 36.25 US$100,000
2026-08-17 2026-08-17 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
1,000
36.25
US$100,000 		1,000 36.25 US$100,000
2026-08-18 2026-08-14 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
1,000 -1.3%
36.23
US$100,000 		1,000 -1.3% 36.23 US$100,000
2026-08-14 2026-08-14 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
243,177
36.23
US$8,809,768 		243,177 36.23 US$8,809,768
2026-07-29 2026-07-27 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -11.0%
34.95
US$6,990,000 		200,000 -11.0% 34.95 US$6,990,000
2026-07-27 2026-07-27 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
34.95
US$6,989,924 		200,000 34.95 US$6,989,924
2026-07-02 2026-06-30 S Sale
3.5
Fitzgerald Meghan
Non-Executive Director
10,000 -18.9%
34.90
US$349,000 		10,000 -18.9% 34.90 US$349,000
2026-06-30 2026-06-30 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
200,000 -10.3%
35.45
US$7,090,000 		200,000 -10.3% 35.45 US$7,090,000
2026-06-30 2026-06-30 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
12,380 -0.1%
35.28
US$436,766 		12,380 -0.1% 35.28 US$436,766
2026-06-30 2026-06-30 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
12,380 -0.1%
35.28
US$436,766 		12,380 -0.1% 35.28 US$436,766
2026-06-30 2026-06-30 S Sale
3.4
QVT Financial LP

Director by Deputization
12,380 -0.1%
35.28
US$436,766 		12,380 -0.1% 35.28 US$436,766
2026-06-30 2026-06-30 PrS Proposed sale
3.5
MEGHAN FITZGERALD

Director

Non-Executive Director
10,000
34.73
US$347,300 		10,000 34.73 US$347,300
2026-06-30 2026-06-30 PrS Proposed sale
3.5
MEGHAN FITZGERALD

Director

Non-Executive Director
10,000
34.73
US$347,300 		10,000 34.73 US$347,300
2026-06-30 2026-06-30 PrS Proposed sale
2.0
KEITH S MANCHESTER

Director

Non-Executive Director
200,000
35.45
US$7,090,280 		200,000 35.45 US$7,090,280
2026-07-01 2026-06-29 S Sale
1.2
Epperly Melissa B,
Non-Executive Director
2,748 -14.3%
34.71
US$95,383 		2,748 -14.3% 34.71 US$95,383
2026-07-01 2026-06-29 S Sale
1.2
Epperly Melissa B,
Non-Executive Director
15,002 -43.8%
34.32
US$514,869 		15,002 -43.8% 34.32 US$514,869
2026-06-30 2026-06-29 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
600,000 -4.2%
34.59
US$20,754,000 		600,000 -4.2% 34.59 US$20,754,000
2026-06-30 2026-06-29 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
200,000 -1.4%
34.44
US$6,888,000 		200,000 -1.4% 34.44 US$6,888,000
2026-06-30 2026-06-29 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
600,000 -4.2%
34.59
US$20,754,000 		600,000 -4.2% 34.59 US$20,754,000
2026-06-30 2026-06-29 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
200,000 -1.4%
34.44
US$6,888,000 		200,000 -1.4% 34.44 US$6,888,000
2026-06-30 2026-06-29 S Sale
3.4
QVT Financial LP

Director by Deputization
600,000 -4.2%
34.59
US$20,754,000 		600,000 -4.2% 34.59 US$20,754,000
2026-06-30 2026-06-29 S Sale
3.4
QVT Financial LP

Director by Deputization
200,000 -1.4%
34.44
US$6,888,000 		200,000 -1.4% 34.44 US$6,888,000
2026-06-29 2026-06-29 PrS Proposed sale
1.2
MELISSA EPPERLY

Director

Non-Executive Director
17,750
34.07
US$604,742 		17,750 34.07 US$604,742
2026-06-30 2026-06-26 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
325,000 -2.2%
34.07
US$11,072,750 		325,000 -2.2% 34.07 US$11,072,750
2026-06-30 2026-06-26 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
300,783 -2.0%
33.92
US$10,202,559 		300,783 -2.0% 33.92 US$10,202,559
2026-06-30 2026-06-26 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
325,000 -2.2%
34.07
US$11,072,750 		325,000 -2.2% 34.07 US$11,072,750
2026-06-30 2026-06-26 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
300,783 -2.0%
33.92
US$10,202,559 		300,783 -2.0% 33.92 US$10,202,559
2026-06-30 2026-06-26 S Sale
3.4
QVT Financial LP

Director by Deputization
325,000 -2.2%
34.07
US$11,072,750 		325,000 -2.2% 34.07 US$11,072,750
2026-06-30 2026-06-26 S Sale
3.4
QVT Financial LP

Director by Deputization
300,783 -2.0%
33.92
US$10,202,559 		300,783 -2.0% 33.92 US$10,202,559
2026-06-29 2026-06-26 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
500,000 -2.6%
34.08
US$17,040,000 		500,000 -2.6% 34.08 US$17,040,000
2026-06-26 2026-06-26 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
500,000
34.08
US$17,039,650 		500,000 34.08 US$17,039,650
2026-06-29 2026-06-25 S Sale
2.3
Sukhatme Mayukh

President & CIO

Executive Director
500,000 -2.6%
34.13
US$17,065,000 		500,000 -2.6% 34.13 US$17,065,000
2026-06-25 2026-06-25 PrS Proposed sale
2.3
MAYUKH SUKHATME

Officer; Director

Executive Director
500,000
34.13
US$17,066,500 		500,000 34.13 US$17,066,500
2026-06-26 2026-06-24 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
46,234 -2.8%
33.51
US$1,549,301 		46,234 -2.8% 33.51 US$1,549,301
2026-06-26 2026-06-24 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
153,766 -8.5%
33.05
US$5,081,966 		153,766 -8.5% 33.05 US$5,081,966
2026-06-24 2026-06-24 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
33.16
US$6,631,659 		200,000 33.16 US$6,631,659
2026-05-22 2026-05-22 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -11.0%
30.27
US$6,054,000 		200,000 -11.0% 30.27 US$6,054,000
2026-05-22 2026-05-22 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
30.27
US$6,054,731 		200,000 30.27 US$6,054,731
2026-04-22 2026-04-20 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -10.8%
29.59
US$5,918,000 		200,000 -10.8% 29.59 US$5,918,000
2026-04-20 2026-04-20 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
29.59
US$5,917,135 		200,000 29.59 US$5,917,135
2026-04-20 2026-04-16 S Sale
2.4
Gline Matthew

CEO

Executive Director
289,774 -1.7%
29.16
US$8,449,810 		289,774 -1.7% 29.16 US$8,449,810
2026-04-16 2026-04-16 PrS Proposed sale
2.4
Gline Matthew

Officer

Officer
289,774
29.16
US$8,449,876 		289,774 29.16 US$8,449,876
2026-04-16 2026-04-16 PrS Proposed sale
2.4
Gline Matthew

Officer

Officer
289,774
29.16
US$8,449,876 		289,774 29.16 US$8,449,876
2026-04-10 2026-04-08 S Sale
0.8
Humes Jennifer

Chief Accounting Officer

Officer
13,538 -13.9%
28.37
US$384,073 		13,538 -13.9% 28.37 US$384,073
2026-04-08 2026-04-08 PrS Proposed sale
0.8
JENNIFER HUMES

Officer

Officer
13,538
28.37
US$384,035 		13,538 28.37 US$384,035
2026-03-30 2026-03-26 S Sale
3.5
Fitzgerald Meghan
Non-Executive Director
70,000 -62.0%
27.45
US$1,921,500 		70,000 -62.0% 27.45 US$1,921,500
2026-03-26 2026-03-26 PrS Proposed sale
3.5
MEGHAN FITZGERALD

Director

Non-Executive Director
70,000
27.45
US$1,921,458 		70,000 27.45 US$1,921,458
2026-03-19 2026-03-17 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -10.8%
28.24
US$5,648,000 		200,000 -10.8% 28.24 US$5,648,000
2026-03-17 2026-03-17 PrS Proposed sale
2.2
Venker Eric

Officer

Officer
200,000
28.24
US$5,648,836 		200,000 28.24 US$5,648,836
2026-03-18 2026-03-16 S Sale
1.2
Epperly Melissa B,
Non-Executive Director
41,861 -72.6%
28.68
US$1,200,573 		41,861 -72.6% 28.68 US$1,200,573
2026-03-16 2026-03-16 PrS Proposed sale
1.2
MELISSA B EPPERLY

Director

Non-Executive Director
41,861
28.68
US$1,200,498 		41,861 28.68 US$1,200,498
2026-02-23 2026-02-23 S Sale
1.8
Torti Frank

President and Vant Chair

Officer
587,390 -4.1%
27.51
US$16,159,099 		587,390 -4.1% 27.51 US$16,159,099
2026-02-23 2026-02-20 S Sale
1.8
Torti Frank

President and Vant Chair

Officer
1,012,610 -6.9%
27.15
US$27,492,362 		1,012,610 -6.9% 27.15 US$27,492,362
2026-02-20 2026-02-20 PrS Proposed sale
1.8
FRANK TORTI

Officer

Officer
1,600,000
27.52
US$44,032,000 		1,600,000 27.52 US$44,032,000
2026-02-23 2026-02-19 S Sale
1.8
Torti Frank

President and Vant Chair

Officer
1,400,000 -9.2%
27.42
US$38,388,000 		1,400,000 -9.2% 27.42 US$38,388,000
2026-02-19 2026-02-19 PrS Proposed sale
1.8
FRANK TORTI

Officer

Officer
1,400,000
27.48
US$38,472,000 		1,400,000 27.48 US$38,472,000
2026-02-18 2026-02-13 S Sale
2.2
Venker Eric

President & Immunovant CEO

Officer
200,000 -10.8%
26.49
US$5,298,000 		200,000 -10.8% 26.49 US$5,298,000
2026-02-13 2026-02-13 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
225,000 -1.5%
26.50
US$5,962,500 		225,000 -1.5% 26.50 US$5,962,500
2026-02-13 2026-02-13 S Sale
3.3
Gold Daniel Allen
Non-Executive Director
150,784 -1.0%
26.49
US$3,994,268 		150,784 -1.0% 26.49 US$3,994,268
2026-02-13 2026-02-13 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
225,000 -1.5%
26.50
US$5,962,500 		225,000 -1.5% 26.50 US$5,962,500
2026-02-13 2026-02-13 S Sale
2.0
MANCHESTER KEITH S
Non-Executive Director
150,784 -1.0%
26.49
US$3,994,268 		150,784 -1.0% 26.49 US$3,994,268
2026-02-13 2026-02-13 S Sale
3.4
QVT Financial LP

Director by Deputization
225,000 -1.5%
26.50
US$5,962,500 		225,000 -1.5% 26.50 US$5,962,500
2026-02-13 2026-02-13 S Sale
3.4
QVT Financial LP

Director by Deputization
150,784 -1.0%
26.49
US$3,994,268 		150,784 -1.0% 26.49 US$3,994,268
Explore more

More insider trading research around Roivant Sciences Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America